9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

ConditionMesotheliomaEstimated Enrollment: 8Age Group: 19 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: F090917002 (UAB 0901)|UAB 0901Study First Received: September 15, 2010Last Updated: May 20, 2016Estimated Primary Completion Date: April 2015Primary Outcome Measures:Evaluation of the tumor response rate following zoledronic acid|Evaluation of the duration of tumor responseSponsors and Collaborators:University of Alabama at Birmingham|Novartis PharmaceuticalsResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01204203...

Continue reading

A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

ConditionCancerEstimated Enrollment: 22Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 2009/337Study First Received: October 15, 2009Last Updated: February 7, 2017Estimated Primary Completion Date: September 2015Primary Outcome Measures:Progression fee survival rate|Response rate according to modified RECIST criteria|Toxicity (CTCAE version 4)|Overall survivalSponsors and Collaborators:University Hospital, Ghent|Merck Sharp & Dohme Corp.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00996567...

Continue reading

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

ConditionAdvanced Malignant Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant MesotheliomaEstimated Enrollment: 34Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCI-2009-00656|CDR0000539269|N0623|U10CA025224Study First Received: April 11, 2007Last Updated: January 28, 2015Estimated Primary Completion Date: April 2009Primary Outcome Measures:Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST)|Overall Survival|Progression-free Survival Assessed by RECIST|Determine the Clinical Toxicities of This Drug in This Participant Population.|Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.|Overall Response...

Continue reading

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

ConditionMalignant Pleural Mesothelioma|Solid TumorsEstimated Enrollment: 71Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CBP08-01Study First Received: June 16, 2008Last Updated: December 19, 2012Estimated Primary Completion Date: July 2012Primary Outcome Measures:Ph I: To determine the MTD of CBP501 + pemetrexed + cisplatin in patients with advanced solid tumors. Ph II: To evaluate the efficacy and safety profile of CBP501 + pemetrexed + cisplatin in patients with malignant pleural mesothelioma|Ph I: To determine the recommended CBP501 dose for exploration in the phase II part|Ph I:...

Continue reading

Isolated Thoracic Perfusion (ITP-F) for MPM

ConditionMesotheliomaEstimated Enrollment: 23Age Group: 18 Years to 80 Years   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case Control|Time Perspective: ProspectiveStudy ID Numbers: 0001Study First Received: May 26, 2015Last Updated: June 9, 2015Estimated Primary Completion Date: January 2015Primary Outcome Measures:Survival|ToxicitySponsors and Collaborators:Medias Klinikum for Surgical OncologyResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02467426...

Continue reading

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

ConditionMesotheliomaEstimated Enrollment: 448Age Group: 18 Years to 75 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: IFCT-GFPC-0701Study First Received: March 29, 2008Last Updated: September 1, 2016Estimated Primary Completion Date: January 2015Primary Outcome Measures:% of patients with controled disease (responder and stable patients) at 6 months|Overall Survival|Number of participants with treatment-related adverse events as assessed by CTCAE v3.0Sponsors and Collaborators:Intergroupe Francophone de Cancerologie Thoracique|University Hospital, Caen|Groupe Francais De Pneumo-CancerologieResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00651456...

Continue reading

Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 45Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: ELCWP-01062Study First Received: March 5, 2008Last Updated: February 11, 2015Estimated Primary Completion Date: March 2009Primary Outcome Measures:Response rate|Survival|ToxicitySponsors and Collaborators:European Lung Cancer Working PartyResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00634205...

Continue reading

Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 30Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: CDR0000066141|P30CA016087|NYU-9850|MDA-FDR001234|MDA-ID-95209|NCI-G99-1575Study First Received: December 10, 1999Last Updated: March 25, 2011Estimated Primary Completion Date: May 2001Primary Outcome Measures:Sponsors and Collaborators:New York University School of Medicine|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00004033...

Continue reading

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 77Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: ONC-2006-003|EUDRACT 2006-004429-27Study First Received: December 4, 2006Last Updated: August 31, 2011Estimated Primary Completion Date: November 2010Primary Outcome Measures:Time to progression (TTP) from first day of treatment until first observation of disease progression or death due to any cause or the last date the patient was known to be progression free or alive.|Response rate (RR) assessed according to modified RECIST criteria for Malignant Pleural Mesothelioma.|Overall survival (OS) computed as the time between the...

Continue reading

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

ConditionAdvanced Malignant Mesothelioma|Recurrent Malignant MesotheliomaEstimated Enrollment: 39Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCI-2009-00693|CDR0000652058|NCIC-183Study First Received: October 25, 2006Last Updated: May 5, 2014Estimated Primary Completion Date: January 2012Primary Outcome Measures:Objective Response (Partial and Complete) Per RECISTSponsors and Collaborators:National Cancer Institute (NCI)Result Received: October 21, 2013Website Link: https://ClinicalTrials.gov/show/NCT00392444...

Continue reading